Clinical Trial Record

Return to Clinical Trials

Early Palliative Care on Quality of Life of Advanced Cancer Patients


2014-11


2016-11


2016-11


281

Study Overview

Early Palliative Care on Quality of Life of Advanced Cancer Patients

This study compares two types of care - Standard Oncology Care (SOC) and SOC with early palliative care (EPC) (started within 8 weeks after diagnosis of advanced disease) to see which is better for improving the quality of life of patients with advanced lung, pancreas, gastric and biliary tract cancer. The study will use FACT-G questionnaire to measure patients' quality of life.

The patients will complete a baseline FACT-G questionnaire and then will be randomized to a study group. Subjects who are randomized to Standard Oncology Care (SOC) will follow up with their treating oncologist. They will consult with the palliative care team at their request or at the request of the treating oncologist or of the family. They will complete FACT-G questionnaire at 12 weeks after enrollment. Subjects who are randomized to the SOC with Early Palliative Care (EPC) will meet with a palliative care team (basically composed by a palliative care physician and a palliative care specialized nurse) at their next medical oncology or infusion visit. They will meet with the palliative care team at least every three weeks. They will complete FACT-G questionnaire at 12 weeks after enrollment.

  • Non-small Cell Lung Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Biliary Tract Cancer
  • OTHER: Early Palliative Care
  • RERSCE35E13

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2016-12-04  

N/A  

2016-12-07  

2016-12-07  

N/A  

2016-12-09  

2016-12-09  

N/A  

2016-12  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Early Palliative Care

Subjects receive standard of care with early palliative care.

OTHER: Early Palliative Care

  • Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. Th
NO_INTERVENTION: Standard of Care

Subjects receive standard of care.

Primary Outcome MeasuresMeasure DescriptionTime Frame
Functional Assessment of Cancer Therapy-General (FACT-G) (Quality of life measure)compare change in QOL from baseline to 12 weeks between study armsChange from baseline to 12 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Survivalfrom date of randomization until date of death or for a minimum of six months
Resource utilization at the end of life (EOL): chemotherapy utilizationpercentage of patients who died, that in the 30 days preceding the death received chemotherapyFrom date of randomization until death or for a minimum of six months after enrollment
Resource utilization at the end of life (EOL): hospital admissionspercentage of patients who died, that in the 30 days preceding the death were admitted to hospitalFrom date of randomization until death or for a minimum of six months after enrollment
Resource utilization at the end of life (EOL): emergency room admissionspercentage of patients who died, that in the 30 days preceding the death went to the emergency roomFrom date of randomization until death or for a minimum of six months after enrollment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Pathologically confirmed metastatic lung (NSCLC), pancreatic, gastric and biliary tract cancer, diagnosed within the previous 8 weeks; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2; age ± 18 years; metastatic or locally advanced disease (but not susceptible of loco-regional treatments); eligibility to first-line chemotherapy ± biological agents; life expectancy more than three months; written informed consent provided; FACT-G questionnaire filled in at enrollment, before the randomization.

  • Exclusion Criteria:

  • Patients already receiving care from the PC service or pretreated with chemotherapy ± biological

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • Regione Emilia-Romagna

  • PRINCIPAL_INVESTIGATOR: VITTORIO FRANCIOSI, M.D., UO ONCOLOGIA MEDICA, AZIENDA OSPEDALIERO-UNIVERSITARIA, PARMA, ITALY

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available